

Influence of drug containing ginger extract on arthritic pain and gastropathy in patients with osteoarthritis

Submission date 07/08/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 26/11/2010	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 26/11/2010	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Vladimir Drozdov

Contact details

Central Scientific Research Institute of Gastroenterology

Shosse Entuziastov,86

Moscow

Russian Federation

111123

+7 (8)495 304 1942

zvopt@yandex.ru

Additional identifiers

Protocol serial number

616-08:612.018;612.4:616.7

Study information

Scientific Title

Influence of drug containing ginger extract on arthritic pain and gastropathy in patients with osteoarthritis: a randomised active controlled clinical trial

Study objectives

Traditional non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX-1,2 expression leading to the lack of prostaglandins (PG). PG play a crucial role in mechanisms of mucosal defense. This drug containing ginger extract inhibits COX-2 and increases PG production in gastric mucosa. It seems to be an alternative to traditional NSAIDs especially in patients with osteoarthritis with risk factors of NSAID-induced gastropathy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Local Ethics Committee of Central Scientific Research Institute of Gastroenterology approved on the 31st August 2007

Study design

Randomised active controlled clinical trial

Primary study design

Intentional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Osteoarthritis, NSAID-induced gastropathy

Interventions

The patients were randomised in two groups, using methods of envelopes, to:

1. Group ZG (n = 21): ginger and glucosamine combination (Zinaxin Glucosamine: 170 mg ginger extract [Zingiber officinalis, EV.EXT 35] and 500 mg glucosamine, as glucosamine sulphate, per capsule, Ferrosan AS, Denmark) 2 capsules orally daily
2. Group DG (n = 22): diclofenac and glucosamine combination (100 mg diclofenac as sodium diclofenac and 1000 mg glucosamine as glucosamine sulphate) daily

The duration of treatment was 28 days.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Ginger extract, diclofenac

Primary outcome(s)

Upper GI lesions (erosion, ulcer) were assessed on the 28 day of treatment with upper GI endoscopy

Key secondary outcome(s)

Gastritis

Completion date

01/06/2009

Eligibility

Key inclusion criteria

1. Aged over 18 years, either sex
2. Osteoarthritis (OA) pain syndrome availability of more than 40 mm according to Visual Analogue Scale (VAS)
3. Requiring anti-inflammatory therapy assignment
4. NSAID-gastropathy or dyspepsia development from NSAID therapy in anamnesis
5. Informed patient consent to administer the preparation
6. Compliance with the listed research protocol

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Ulcer presence during upper gastrointestinal (GI) endoscopy and more than 5 stomach mucosa and/or duodenum erosions, and/or erosive oesophagitis
2. High risk of cardiological complications, arterial hypertension, cardiac insufficiency greater than II degree, myocardial infarction or apoplectic attack in anamnesis during the previous 3 years, chronic kidney disease, liver insufficiency, bronchial asthma, subcompensated or decompensated diabetes mellitus, oncological diseases
3. NSAID administration, aspirin in anti-aggregant doses, glucocorticosteroids
4. Pregnancy

Date of first enrolment

01/06/2008

Date of final enrolment

01/06/2009

Locations

Countries of recruitment

Russian Federation

Study participating centre

Central Scientific Research Institute of Gastroenterology

Moscow

Russian Federation

111123

Sponsor information

Organisation

Central Scientific Research Institute of Gastroenterology (Russia)

Funder(s)

Funder type

Research organisation

Funder Name

Central Scientific Research Institute of Gastroenterology (Russia) - Healthcare Department

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration